📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-21 16:10
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
16 announcements match the current filters (relevance ≥ 5).
Ind-Ra Assigns 'IND BBB+/Stable' to Bhagiradha Chem's Arm for ₹600 Cr Facilities
India Ratings and Research (Ind-Ra) has assigned 'IND BBB+/Stable/IND A2+' to the ₹600 Cr (INR 6,000 million) bank loan facilities of Bheema Fine Chemicals Private Limited, a wholly owned subsidiary of Bhagiradha Chemicals. The rating is backed by an unconditional and irrevocable corporate guarantee from the parent. Ind-Ra highlighted the ongoing ₹950 Cr total capex outlay to add 9,000 MTPA capacity, of which ₹600 Cr was incurred by June 2026. The expansion will lift aggregate capacity from 3,250 MTPA to 12,250 MTPA, with the subsidiary expected to contribute ~70% of consolidated business upon full ramp-up.
Confidence: HIGH
What changedCredit rating agency Ind-Ra assigned an investment-grade rating of IND BBB+/Stable for ₹600 Cr bank facilities of subsidiary Bheema Fine Chemicals.
Why it mattersSecures banking lines and formalizes credit evaluation for Bhagiradha's massive ₹950 Cr expansion project (larger than its FY26 revenue of ₹536 Cr), which nearly quadruples group manufacturing capacity.
Rated Bank Loan Facilities: INR 6,000 millionTotal Project Capex Outlay: INR 9,500 millionCapex Incurred (June 2026): INR 6,000 millionCapacity Addition: 9,000 MTPATotal Group Capacity post-capex: 12,250 MTPA
📅 Short termReaffirms banking and funding stability for the subsidiary's ongoing capex without near-term refinancing pressures.
📈 Long termThe 9,000 MTPA expansion significantly improves backward integration, reduces raw material dependency on China, and could structurally scale consolidated revenues by FY28.
⚠ Risk flags
- Elevated consolidated net leverage (4.3x net debt/EBITDA in FY26) due to debt-funded capex.
- Execution and stabilization risks for Phase 2 capacity expansion.
- High working capital intensity and agrochemical regulatory risks.
Key Highlights
Ind-Ra assigned 'IND BBB+/Stable/IND A2+' rating for ₹600 Cr (INR 6,000 million) bank loan facilities of subsidiary Bheema Fine Chemicals.
Parent BCIL provides an unconditional and irrevocable corporate guarantee for the subsidiary's facilities.
Total capex outlay of ₹950 Cr (₹9,500 million) across FY24-FY28, with ₹600 Cr already incurred by end-June 2026.
Capex will expand group technical manufacturing capacity by 9,000 MTPA to 12,250 MTPA, contributing ~70% to consolidated revenue upon full commissioning.
👀 What to Watch
Track the commissioning and utilization ramp-up of Phase 2 capacity across FY27-FY28 and monitor debt reduction as operating cash flows normalize.
58% Revenue Growth in Q1 FY27; EBITDA Jumps 240% on Bheema Plant Ramp-up
Bhagiradha Chemicals reported a strong Q1 FY27 with consolidated revenue reaching ₹195.0 Cr, a 58% YoY increase. EBITDA surged 240% YoY to ₹30.5 Cr, with margins expanding significantly to 15.7% from 7.3% in the year-ago period. This performance was driven by the ramp-up of the Bheema Fine Chemicals facility, where capacity utilization nearly doubled compared to Q4 FY26. The company also introduced four new mid-to-high value molecules, contributing to a richer product mix and improved realizations.
Confidence: HIGH
What changedThe company has transitioned from a heavy capex phase (₹450 Cr invested in Bheema) to an operational ramp-up phase, resulting in its highest-ever quarterly performance.
Why it mattersThe new Bheema facility nearly triples the company's total capacity (9,002 MT vs 3,250 MT standalone) and focuses on higher-margin products, structurally improving the company's profitability profile.
Q1 FY27 Revenue: ₹195.0 CrYoY Revenue Growth: 58%EBITDA Margin: 15.7%Bheema Plant Capex: ₹450 CrBheema Plant Capacity: 9,002 MTQ1 Revenue vs TTM Revenue: 36.4%
📅 Short termThe stock may react positively to the sharp recovery in margins and the 'highest-ever' quarterly revenue and profit figures.
📈 Long termStructural growth is expected as the Bheema facility scales up and the company reduces its reliance on low-margin products at its older facility.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High dependency on China for 20-25% of raw materials
- Geopolitical risks affecting crude-linked input prices
- Regulatory uncertainty regarding Chlorpyriphos
Key Highlights
Revenue from operations grew 58% YoY to ₹195.0 Cr in Q1 FY27.
EBITDA increased 240% YoY to ₹30.5 Cr, with margins expanding by 839 bps to 15.7%.
Profit After Tax (PAT) rose 235% YoY to ₹13.3 Cr, despite higher depreciation and finance costs.
Introduced 4 new molecules in the mid-to-high value segment during the quarter.
Bheema Fine Chemicals facility (9,002 MT capacity) saw utilization nearly double vs Q4 FY26.
👀 What to Watch
Watch for the continued utilization ramp-up at the Bheema facility and the successful commercialization of the remaining 6 out of 10 new products under development to sustain margin expansion.
235% YoY Profit Growth: BHAGCHEM Reports Strong Q1 FY27 Consolidated Results
Bhagiradha Chemicals reported a robust start to FY27 with consolidated revenue growing 57.5% YoY to ₹195.02 Cr. Net profit surged 235% YoY to ₹13.33 Cr, compared to ₹3.98 Cr in the same quarter last year. The performance indicates strong operating leverage as the Bheema Fine Chemicals subsidiary scales up, with Q1 revenue alone representing 36.4% of the previous TTM revenue. Despite higher finance costs of ₹6.43 Cr, consolidated PBT rose 601% YoY, reflecting improved product realizations and capacity utilization.
Confidence: HIGH
What changedThe company has reported a significant turnaround in profitability and revenue growth, moving from a TTM PAT of ₹18 Cr to a single-quarter PAT of ₹13.33 Cr.
Why it mattersThis result validates the company's ₹800+ Cr expansion strategy at its Bheema subsidiary, showing that the new capacity is contributing meaningfully to both top-line growth and bottom-line margins despite global industry headwinds.
Consolidated Revenue (Q1): ₹195.02 CrConsolidated Net Profit (Q1): ₹13.33 CrQ1 Revenue vs TTM Revenue: 36.4%Q1 Profit vs TTM Profit: 74.0%Finance Costs (Q1): ₹6.43 Cr
📅 Short termThe stock is likely to react positively in the short term due to the massive earnings beat and significant margin expansion compared to the previous four quarters.
📈 Long termStructurally positive as the company scales its 9,002 MT capacity at Bheema; however, the high P/E ratio of 214.8 requires sustained high growth to justify current valuations.
⚠ Risk flags
- High finance costs (₹6.43 Cr per quarter)
- Low promoter holding (19.6%)
- Regulatory risk regarding Chlorpyriphos ban
- Raw material dependency on China (20-25%)
Key Highlights
Consolidated Revenue from Operations increased 57.5% YoY to ₹195.02 Cr from ₹123.78 Cr.
Consolidated Net Profit grew 235% YoY to ₹13.33 Cr, up from ₹3.98 Cr in Q1 FY26.
Consolidated Profit Before Tax (PBT) reached ₹17.54 Cr, a 601% increase over the ₹2.50 Cr reported in the year-ago period.
Inventory levels for finished goods and WIP increased by ₹50.32 Cr during the quarter, suggesting strong anticipated demand.
Finance costs rose to ₹6.43 Cr from ₹3.26 Cr YoY, reflecting the debt servicing for the ₹800+ Cr Bheema expansion.
👀 What to Watch
Investors should monitor the sustainability of the 15.6% estimated EBITDA margin and the ramp-up progress of the Bheema Fine Chemicals facility. Key risks to watch include the potential regulatory ban on Chlorpyriphos and the impact of high finance costs on net margins.
BHAGCHEM Q1 FY27: Consolidated Revenue up 57% YoY to ₹195 Cr; PBT jumps 7x to ₹17.5 Cr
Bhagiradha Chemicals reported a strong start to FY27 with consolidated revenue reaching ₹195.02 Cr, a 57.5% increase over Q1 FY26. Profitability showed a sharp recovery, with Consolidated Profit Before Tax (PBT) rising to ₹17.54 Cr from just ₹2.50 Cr in the year-ago period. This growth is largely driven by the ramp-up of the Bheema Fine Chemicals subsidiary, which added 9,002 MT of capacity. However, finance costs have doubled to ₹6.43 Cr YoY, reflecting the capital-intensive nature of recent expansions.
Confidence: HIGH
What changedThe company has achieved a significant jump in quarterly revenue run-rate (₹195 Cr vs TTM average of ₹134 Cr) following its capacity expansion.
Why it mattersThe results validate the ₹800+ Cr investment in the Bheema subsidiary, showing that the new capacity is translating into both top-line growth and improved operational leverage.
Consolidated Revenue (Q1): ₹195.02 CrYoY Revenue Growth: 57.5%Q1 Revenue vs TTM Revenue: 36.4%Consolidated PBT: ₹17.54 CrFinance Costs: ₹6.43 Cr
📅 Short termThe stock may react positively to the sharp jump in consolidated profitability and revenue growth that exceeds historical quarterly averages.
📈 Long termStructural growth depends on the successful integration of the Bheema facility and the development of 10 new products to diversify the portfolio.
⚠ Risk flags
- High finance costs relative to quarterly PAT
- Chinese oversupply impacting global pricing power
- High valuation with a P/E exceeding 200
Key Highlights
Consolidated Revenue from Operations grew 57.5% YoY to ₹195.02 Cr from ₹123.78 Cr.
Consolidated Profit Before Tax (PBT) surged to ₹17.54 Cr compared to ₹2.50 Cr in Q1 FY26.
Standalone Net Profit increased to ₹10.68 Cr, up from ₹8.29 Cr in the same quarter last year.
Finance costs rose significantly to ₹6.43 Cr from ₹3.26 Cr YoY, reflecting debt for the Bheema expansion.
Consolidated inventory levels saw a net increase of ₹50.32 Cr during the quarter, indicating production ramp-up.
👀 What to Watch
Monitor the sustainability of operating margins as the Bheema facility scales up and watch for any impact from global agrochemical pricing volatility due to Chinese oversupply.
Bhagiradha Chemicals FY26 PAT Grows 31% to ₹18.2 Cr; EBITDA Surges 55% on Capacity Expansion
Bhagiradha Chemicals reported a strong financial performance for FY26, with consolidated revenue rising 22% to ₹535.9 crore and EBITDA increasing 55% to ₹57.1 crore. The growth was driven by a combination of volume expansion and improved value realizations, alongside the successful commencement of Phase I of the Bheema Fine project (₹400 crore capitalization). While PAT grew 31% to ₹18.2 crore, the bottom line was partially moderated by higher depreciation and finance costs associated with the new facility. Management has set an ambitious long-term target to scale revenue by 3.5x over the next 4-5 years.
Key Highlights
FY26 Revenue grew 22% YoY to ₹535.9 crore, while EBITDA margins expanded from 8.4% to 10.7%.
Q4FY26 EBITDA surged 220% YoY to ₹19.4 crore, reflecting strong operating leverage and improved capacity utilization.
Successfully commissioned Phase I of Bheema Fine Chemicals with an incremental capacity potential of 9,002 MTPA.
Launched 3 new molecules and added 19 new customers, including 5 major accounts, during the fiscal year.
Board recommended a final dividend of ₹0.15 (15%) per equity share of face value ₹1.
👀 What to Watch
Investors should focus on the utilization ramp-up of the Bheema Fine facility in FY27, which is expected to be a primary growth driver. The company's aggressive 4-5 year revenue target and focus on backward integration make it a strong candidate for long-term monitoring in the agrochemical space.
Bhagiradha Chemicals FY26 Revenue Rises 19% to ₹521 Cr; Recommends ₹0.15 Dividend
Bhagiradha Chemicals reported a strong 19.4% year-on-year growth in annual revenue, reaching ₹521.22 crore for FY26. While full-year profit after tax saw a marginal decline to ₹26.24 crore from ₹27.39 crore, the Q4 performance was robust with net profit rising 39.6% YoY to ₹7.21 crore. The Board has recommended a final dividend of ₹0.15 per share (15% of face value). Additionally, the company has transitioned to a lower corporate tax rate of 22% effective April 1, 2025.
Key Highlights
Annual Revenue from Operations grew 19.4% YoY to ₹52,122.21 lakhs in FY26.
Q4 FY26 Profit After Tax increased by 39.6% YoY to ₹720.61 lakhs compared to ₹516.20 lakhs in Q4 FY25.
Recommended a final dividend of ₹0.15 per equity share (15%) for the financial year ended March 31, 2026.
Total Assets increased to ₹94,810.20 lakhs as of March 31, 2026, from ₹91,384.03 lakhs in the previous year.
Company opted for a concessional corporate tax rate of 22% starting FY26, resulting in a deferred tax liability reduction of ₹307.75 lakhs.
👀 What to Watch
The strong Q4 recovery and healthy revenue growth indicate positive momentum in the crop protection segment. Investors should monitor if the transition to a lower tax regime and improved Q4 margins lead to sustained profit growth in FY27.
Bhagiradha Chemicals Recommends ₹0.15 Final Dividend for FY 2025-26
The Board of Directors of Bhagiradha Chemicals & Industries Limited has recommended a final dividend of ₹0.15 per equity share for the financial year ended March 31, 2026. This dividend represents a 15% payout on the face value of ₹1 per share. The proposal is subject to shareholder approval at the 33rd Annual General Meeting scheduled for July 31, 2026. The company has established July 23, 2026, as the record date for determining eligible shareholders.
Key Highlights
Recommended final dividend of ₹0.15 per equity share of face value ₹1 each
Dividend payout ratio stands at 15% of the face value
Record date for dividend eligibility is set for Thursday, July 23, 2026
Book closure period scheduled from July 24, 2026, to July 31, 2026
Final approval to be sought at the 33rd AGM on July 31, 2026
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the record date of July 23, 2026. While the absolute dividend amount is small, it reflects the company's commitment to returning capital to shareholders.
Bhagiradha Chemicals Recommends Rs 0.15 Final Dividend; Sets Record Date for July 23, 2026
Bhagiradha Chemicals & Industries Limited has recommended a final dividend of Rs 0.15 per equity share for the financial year ended March 31, 2026. This payout represents 15% of the face value of Re 1 per share. The company has fixed July 23, 2026, as the record date to determine shareholder eligibility for the dividend. The final distribution is subject to approval at the 33rd Annual General Meeting scheduled for July 31, 2026.
Key Highlights
Recommended final dividend of Rs 0.15 per equity share of face value Re 1 each.
Dividend payout ratio stands at 15% for the financial year 2025-26.
Record date for dividend entitlement is fixed as Thursday, July 23, 2026.
Book closure period announced from July 24, 2026, to July 31, 2026.
33rd Annual General Meeting (AGM) to be held on Friday, July 31, 2026.
👀 What to Watch
Investors seeking to receive the dividend should ensure they hold the shares before the ex-dividend date, which typically falls one business day prior to the July 23 record date. The yield is relatively low, so the focus should remain on the company's core business performance.
Bhagiradha Chemicals FY26 Revenue Up 19.4%, Recommends ₹0.15 Dividend; Record Date July 23
Bhagiradha Chemicals reported a strong 19.4% YoY growth in annual revenue to ₹52,122 Lakhs for FY26, although full-year net profit saw a slight decline to ₹2,623 Lakhs from ₹2,739 Lakhs. The fourth quarter (Q4 FY26) was particularly robust, with revenue rising 21.6% YoY and net profit jumping 39.6% to ₹720.61 Lakhs. The company has recommended a final dividend of ₹0.15 per share (15% of face value) and has transitioned to a lower 22% corporate tax rate. The record date for the dividend is set for July 23, 2026.
Key Highlights
Annual Revenue from Operations increased 19.4% YoY to ₹52,122.21 Lakhs in FY26.
Q4 FY26 Net Profit surged 39.6% YoY to ₹720.61 Lakhs compared to ₹516.20 Lakhs in the previous year's quarter.
Recommended a final dividend of ₹0.15 per equity share (15% of face value) for FY26.
Full-year EPS stood at ₹2.02, a slight decrease from ₹2.25 in FY25 due to higher operating expenses.
Adopted a concessional 22% tax rate, resulting in a ₹307.75 Lakhs reduction in deferred tax liability.
👀 What to Watch
Investors should view the strong Q4 performance as a positive sign of recovery in margins. The stock offers a steady dividend, and the record date of July 23 should be noted for eligibility.
Bhagiradha Chemicals Q4 Net Profit Jumps 39% to ₹7.21 Cr; Declares ₹0.15 Dividend
Bhagiradha Chemicals reported a strong Q4 FY26 with revenue from operations growing 21.6% YoY to ₹149.16 crore. Net profit for the quarter rose significantly by 39.6% YoY to ₹7.21 crore, up from ₹5.16 crore in the previous year. For the full fiscal year 2026, revenue increased by 19.4% to ₹521.22 crore, although annual net profit saw a slight dip of 4.2% to ₹26.24 crore. The Board has recommended a final dividend of ₹0.15 per share (15%) for the financial year.
Key Highlights
Q4 FY26 Revenue from operations rose 21.6% YoY to ₹14,916.17 Lakhs.
Q4 FY26 Net Profit increased 39.6% YoY to ₹720.61 Lakhs from ₹516.20 Lakhs.
Full-year FY26 Revenue reached ₹52,122.21 Lakhs compared to ₹43,635.74 Lakhs in FY25.
Recommended a final dividend of ₹0.15 per equity share of face value ₹1.
Finance costs for the full year increased to ₹1,138.76 Lakhs from ₹664.12 Lakhs in the previous year.
👀 What to Watch
The strong Q4 recovery suggests improving operational efficiency; investors should monitor if this momentum continues into FY27. The stock remains a watch for those interested in the crop protection chemicals sector given the steady revenue growth.
Bhagiradha Chemicals Credit Rating Affirmed at IND BBB+; Outlook Revised to Stable
India Ratings and Research (Ind-Ra) has affirmed the credit ratings for Bhagiradha Chemicals & Industries Limited's bank loan facilities totaling INR 1,730 million. While the long-term rating remains at 'IND BBB+' and the short-term rating at 'IND A2+', the outlook has been revised from 'Positive' to 'Stable'. This revision suggests a moderation in the expectations for immediate credit profile improvement compared to the previous assessment. The rated facilities include working capital limits and term loans from major lenders including SBI, Axis Bank, RBL, and ICICI Bank.
Key Highlights
India Ratings affirmed the long-term rating at 'IND BBB+' and short-term rating at 'IND A2+'
The outlook for the company's bank facilities was revised from 'Positive' to 'Stable'
Total bank loan facilities rated amount to INR 1,730 million (INR 173 Crores)
The facilities include a specific term loan of INR 328.40 million from Axis Bank
Lenders involved include State Bank of India, Axis Bank, RBL Bank, and ICICI Bank
👀 What to Watch
Investors should note the revision in outlook to 'Stable', which indicates a steady credit profile but slower improvement than previously anticipated. Monitor the company's debt-to-equity and interest coverage ratios in upcoming quarterly results.
Bhagiradha Chemicals Q3FY26 EBITDA Jumps 49% YoY; Gross Margins Expand to 43%
Bhagiradha Chemicals reported a steady Q3FY26 with revenue growing 11% YoY to ₹114 Cr, driven by improved price realizations despite a seasonal volume dip. EBITDA saw a significant 49% YoY increase to ₹13.7 Cr as gross margins expanded by 311 bps to 43% due to a favorable product mix and process improvements. However, 9MFY26 PAT declined slightly by 4% YoY to ₹14.1 Cr, primarily due to higher finance costs from working capital utilization and increased depreciation. The company is aggressively pursuing an ₹800 Cr expansion plan, with Phase 1 of the Bheema facility now ready for a production ramp-up.
Key Highlights
Q3FY26 EBITDA grew 49% YoY to ₹13.7 Cr with margins expanding to 12.0% from 8.9% YoY.
Gross margins reached 43.0% in Q3FY26, a 311 bps YoY improvement led by process upgrades and better product mix.
9MFY26 revenue rose 19% YoY to ₹377.8 Cr, supported by double-digit growth in average price realizations.
Total capex plan of ₹800 Cr is underway, including a ₹70 Cr solar project and ₹350 Cr allocated for Phase 2.
Phase 1 of the Bheema facility is geared for a structured ramp-up of 5 to 8 molecules over the next 3 months.
👀 What to Watch
Investors should focus on the successful ramp-up of the Bheema facility which is key to achieving the company's long-term revenue targets. While high interest costs are currently weighing on PAT, the significant expansion in gross margins indicates strong operational efficiency and pricing power.
Bhagiradha Chemicals Appoints Ranjit Kumar Kilaru as New CFO Effective March 1, 2026
Bhagiradha Chemicals & Industries has announced a leadership transition in its finance department. Mr. B. Krishna Mohan Rao will retire as the Chief Financial Officer on February 28, 2026. He will be succeeded by Mr. Ranjit Kumar Kilaru, who takes over the role on March 1, 2026. Mr. Kilaru is a Chartered Accountant with over 23 years of experience in banking and manufacturing, including a 13-year tenure at Axis Bank.
Key Highlights
Retirement of Mr. B. Krishna Mohan Rao as CFO effective February 28, 2026.
Appointment of Mr. Ranjit Kumar Kilaru as the new CFO starting March 1, 2026.
Incoming CFO brings 23+ years of experience across banking, manufacturing, and financial advisory.
Mr. Kilaru previously served as Deputy Vice President and Centre Head – SME at Axis Bank for 13 years.
The transition includes updating the list of Key Managerial Personnel authorized for materiality determinations.
👀 What to Watch
Investors should view this as a routine management transition; however, the new CFO's extensive banking and debt syndication background may benefit the company's future capital structuring. No immediate action is required other than monitoring for any shifts in financial reporting or strategy.
Bhagiradha Chemicals Appoints Ranjit Kumar Kilaru as CFO; B. Krishna Mohan Rao to Retire
Bhagiradha Chemicals & Industries Limited has announced a leadership transition in its finance department. Mr. B. Krishna Mohan Rao will retire from his position as Chief Financial Officer and Key Managerial Personnel effective February 28, 2026. He will be succeeded by Mr. Ranjit Kumar Kilaru, a Chartered Accountant with over 23 years of experience, starting March 1, 2026. Mr. Kilaru's extensive background includes 17 years in banking, notably serving as Deputy Vice President at Axis Bank.
Key Highlights
Mr. B. Krishna Mohan Rao to retire as CFO and KMP effective February 28, 2026.
Mr. Ranjit Kumar Kilaru appointed as the new CFO and KMP effective March 1, 2026.
Incoming CFO Ranjit Kumar Kilaru brings over 23 years of post-qualification experience in banking and manufacturing.
Mr. Kilaru previously spent 13 years at Axis Bank, leading SME credit and relationship management teams.
👀 What to Watch
Investors should monitor the transition for any changes in financial strategy, though the planned nature of the retirement suggests operational continuity. No immediate action is required as the new CFO brings significant institutional banking experience.
BHAGCHEM Q3 Net Profit Drops 32.3% YoY to ₹4.83 Cr; Appoints New CFO
Bhagiradha Chemicals reported a 10.9% YoY increase in revenue to ₹113.92 crore for Q3 FY26, yet net profit declined significantly by 32.3% to ₹4.83 crore. On a sequential basis, performance was weaker with revenue and profit falling 15.2% and 18.4% respectively compared to Q2 FY26. The company is undergoing a leadership transition as CFO Mr. B. Krishna Mohan Rao retires, to be succeeded by Mr. Ranjit Kumar Kilaru, a CA with 23 years of experience, effective March 1, 2026. Despite 18.6% revenue growth in the nine-month period, overall profitability remains under pressure compared to the previous year.
Key Highlights
Revenue from operations grew 10.9% YoY to ₹113.92 crore in Q3 FY26.
Net profit for the quarter fell 32.3% YoY to ₹4.83 crore from ₹7.13 crore in the previous year.
Nine-month (9M FY26) revenue increased to ₹372.06 crore, up from ₹313.72 crore in 9M FY25.
Finance costs for the nine-month period rose sharply to ₹8.39 crore from ₹5.28 crore YoY.
Appointment of Mr. Ranjit Kumar Kilaru as CFO effective March 01, 2026, following the retirement of the incumbent.
👀 What to Watch
Investors should be cautious as the company is facing margin compression despite revenue growth, likely due to rising operational and finance costs. Monitor how the new CFO manages the debt syndication and financial structuring to improve the bottom line.
Bhagiradha Chemicals Q3 PAT Drops 32% YoY to ₹4.83 Cr; Appoints New CFO
Bhagiradha Chemicals reported a 32.3% year-on-year decline in net profit to ₹4.83 crore for Q3 FY26, down from ₹7.13 crore in the previous year. While revenue from operations grew 10.9% YoY to ₹113.92 crore, it saw a sequential decline of 15.2% from the September quarter. The profitability was impacted by a sharp drop in 'Other Income' and rising finance costs, which surged to ₹8.39 crore for the nine-month period. Additionally, the company announced a leadership transition with Mr. Ranjit Kumar Kilaru taking over as CFO from March 1, 2026.
Key Highlights
Net Profit for Q3 FY26 fell to ₹4.83 crore vs ₹7.13 crore in Q3 FY25, a 32.3% decrease.
Revenue from operations stood at ₹113.92 crore, up 10.9% YoY but down 15.2% QoQ.
Finance costs for the nine-month period increased significantly to ₹8.39 crore from ₹5.28 crore YoY.
Other Income for the quarter plummeted to ₹0.74 crore compared to ₹5.50 crore in the year-ago period.
Appointment of Mr. Ranjit Kumar Kilaru as CFO effective March 01, 2026, following the retirement of Mr. B. Krishna Mohan Rao.
👀 What to Watch
Investors should remain cautious as the company is experiencing margin compression and rising interest burdens despite top-line growth. The management transition at the CFO level should be monitored for any shifts in financial strategy or debt management.
